Speciality Medicines Ltd IPO

The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.

The company is subject to strict technical specifications, quality requirements by its customers. The company failures to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact its business, results of warranty claims.

The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations.

The company limited operating history may make it challenging for investors to assess its future growth prospects and overall business performance since the company was incorporated on February 05, 2021, which makes it a relatively new entity with a short track record of business and financial activities.

The company business is working capital intensive. If its unable to borrow to meet the company working capital requirements, it may materially and adversely affect its business and results of operations.

The company has not yet placed orders in relation to the funding Capital Expenditure towards establishment of Research and Development (R&D) Center comprising Construction of Building and Lab equipment which is proposed to be financed from the Issue proceeds of the IPO. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the building and equipment in a timely manner, or at all, may result in time and cost over-runs and its business, prospects and results of operations may be adversely affected. Its proposed Research and Development (R&D) Center plans are subject to the risk of unanticipated delays in implementation due to factors including delays in construction, obtaining regulatory approvals in timely manner and cost overruns.

Delay in registration of Products in multiple geographical locations across the world may affect its revenue generation and overall financial performance.

The company requires a number of approvals, licences, registrations and permits in the ordinary course of its business and any failures or delay in obtaining the same in a timely manner may adversely affect the company operations.

The products that the company commercialize may not perform as expected which could adversely affect its business, financial condition and results of operations.

The Company does not have any experience in Research and Development Activities and will be depending on professional staff to be appointed by the Company.